Business
Apyx sells helium plasma technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgery.
Apyx revenue rose 9.9%, net loss narrowed to $11.2M, and free cash flow improved but stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Helium plasma medical technologyNote
- Revenue — Revenue rose 9.9% to $52.8MOK
- Profitability — Net loss narrowed to $11.2MNote
- Cash — FCF improved to negative $9.1MNote
- Balance sheet — Debt flat; equity up 2.3%Note
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Apyx Medical Corp reports it. History and quarterly detail are in the app.
- Surgical Aesthetics$45.3M
- OEM$7.5M
Leadership changes
From Apyx Medical Corp's own filings, the day they're filed.
- Shawn Roman · Chief Operating Officer · appointmenteff. 2025-01-28
- Andrew Makrides · Chairman · departureeff. 2024-05-07
- Stavros G. Vizirgianakis · Chairman · departureeff. 2024-05-07
Latest filings
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-24
- DEF 14A · Annual proxy (pay & governance)2026-06-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Apyx Medical Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.